Logo
x

Search

Subscribe Now

Zealand Pharma

Zealand Pharma Submits an NDA for Glepaglutide to the US FDA for the Treatment of Short Bowel Syndrome (SBS)

Zealand Pharma Submits an NDA for Glepaglutide to the US FDA for the Treatment of Short Bowel Syndrome (SBS)

  • December 26, 2023
Zealand Pharma Reports Part 1 Results of Multiple Ascending Dose Trial for ZP8396 for the Management of Overweight and Obesity

Zealand Pharma Reports Part 1 Results of Multiple Ascending Dose Trial for ZP8396 for the Management of Overweight and Obesity

  • July 3, 2023
Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes

Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes

  • March 28, 2023
Zealand Pharma Reports P-III (EASE 1) Trial Results of Glepaglutide for the Treatment of Short Bowel Syndrome

Zealand Pharma Reports P-III (EASE 1) Trial Results of Glepaglutide for the Treatment of Short Bowel Syndrome

  • September 30, 2022
Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism

Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism

  • February 15, 2022
PharmaShots Interview: Zealand Pharma's Dr. David Kendall Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

PharmaShots Interview: Zealand Pharma's Dr. David Kendall Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Ad...

  • September 27, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.